AHA Science (@AHAScience) header
AHA Science (@AHAScience) profile picture

AHA Science

@AHAScience

@American_Heart’s official account for meetings, science news, funding opportunities and membership. RTs/Follows not endorsements. Pump up your career, here.

 Dallas, TX
professional.heart.org/
Joined January 2009
  • Tweets13.8K
  • Following4.7K
  • Followers76.1K
US Veterans make up more than 5% of the US adult population. Compared with the general US population, Veterans are older, have more comorbidities, and face unique structural barriers, including high rates of rural location and less internet access. With time, the makeup of Veterans is becoming increasingly diverse in race, ethnicity, age, gender, and military exposure history. Veterans receiving care in the Veterans Administration (VA) have higher rates of obesity, diabetes, hyperlipidemia, hypertension, and sleep disorders compared to the general population. Data from the Million Veteran Program show that fewer than 5% of Veterans achieve optimal cardiovascular health based on the American Heart Association’s Life’s Essential 8 domains, which in turn has been associated with reduced life expectancy. ✍🏼 @yuanneal @AIDALMARZOOQ @wccushman @jenmartinsleeps @Lisa_Jackson_MD 📷 Meeting the cardiovascular health promotion needs of US veterans: challenges and responses. professional.heart.org/en/sc…
A journal article titled "Cardiovascular Health Promotion for US Veterans: Current State, Gaps, and Strategies: A Scientific Statement from the American Heart Association" published in Circulation. The document includes a list of authors and affiliations, followed by an abstract summarizing the statement's focus on cardiovascular health, disparities, and strategies for US veterans. The article emphasizes the importance of holistic health approaches and support from the Veterans Health Administration.

ALT A journal article titled "Cardiovascular Health Promotion for US Veterans: Current State, Gaps, and Strategies: A Scientific Statement from the American Heart Association" published in Circulation. The document includes a list of authors and affiliations, followed by an abstract summarizing the statement's focus on cardiovascular health, disparities, and strategies for US veterans. The article emphasizes the importance of holistic health approaches and support from the Veterans Health Administration.

This image is an infographic titled "Cardiovascular Health Promotion Goals (Life’s Essential 8)." It features various icons representing different health goals, such as healthy eating, physical activity, and managing blood pressure. Below, it addresses challenges in veteran populations, including service-related exposures and high rates of chronic disease. It also lists VA initiatives like rural care initiatives and comprehensive women's health care. The layout is structured in three blocks with colorful icons and text.

ALT This image is an infographic titled "Cardiovascular Health Promotion Goals (Life’s Essential 8)." It features various icons representing different health goals, such as healthy eating, physical activity, and managing blood pressure. Below, it addresses challenges in veteran populations, including service-related exposures and high rates of chronic disease. It also lists VA initiatives like rural care initiatives and comprehensive women's health care. The layout is structured in three blocks with colorful icons and text.

3
5
15
1,520
In case you missed it, here are all late breaking clinical trial results from #ScientificSessions26.
A table titled "AHA Scientific Sessions 2026 — Late-Breaking Science I-VI" in Chicago, IL, from November 6-9, 2026. The table has four columns: Trial Acronym, Title, Topics of Focus, and Results. The table includes various studies related to cardiovascular topics with acronyms and brief descriptions. AHA logo is visible at the top.

ALT A table titled "AHA Scientific Sessions 2026 — Late-Breaking Science I-VI" in Chicago, IL, from November 6-9, 2026. The table has four columns: Trial Acronym, Title, Topics of Focus, and Results. The table includes various studies related to cardiovascular topics with acronyms and brief descriptions. AHA logo is visible at the top.

A table from the AHA Scientific Sessions 2026 details late-breaking science presentations. It includes columns for trial acronym, title, topics of focus, and results. The event is scheduled for November 6-9, 2026, in Chicago, IL.

ALT A table from the AHA Scientific Sessions 2026 details late-breaking science presentations. It includes columns for trial acronym, title, topics of focus, and results. The event is scheduled for November 6-9, 2026, in Chicago, IL.

3
45
128
8,285
Patients with CKM syndrome often have multiple conditions requiring care from several clinicians, which can lead to fragmentation of care. Incorporating clinical input from multiple disciplines within the CKM framework and coordinating care among team members are essential components of holistic CKM care. The need for a point person is emphasized, to coordinate efforts of the CKM interdis¬ciplinary team, to facilitate implementation of evidence-based care and guideline-directed medical therapy and to support patients and clinicians. professional.heart.org/en/sc… ✍🏼 @ChiadiNdumele @HeartDocSadiya @kardiologykazi @noshreza @virani_md @biykemb @NutritionHF @mandeepbajaj65 @KatherineTuttl8 @RangaswJ @lisaVWMD @KBreathettMD @EmoryFamMed @ShoaClarke @mad_sters @jmortonmd @sripalbangalore @AnumSaeedMD
Image from AHA Science (@AHAScience)
2
6
23
1,650
AI is transforming cardiovascular care at the point of care, creating new opportunities to close the gap between scientific discovery and patient care. At #ScientificSessions26, past American Heart Association President Bob Harrington, MD, FAHA and OpenAI's Nate Gross, MD, explored how AI can help accelerate the future of medicine. 💡 @HeartBobH, @NG
2
7
18
1,361
As #ScientificSessions26 comes to a close, we celebrate the science, innovation and collaboration that continue to shape the future of cardiovascular and brain health. Now, we look ahead to a historic milestone. Join us in Boston for the 100th Scientific Sessions, Nov. 5-8, 2027. @HeartDocSadiya @bnallamo #ScientificSessions27
1
11
2
36
2,844
Replying to @AnastasiaSMihai
@AnastasiaSMihai discusses late breaking science from ATTAIN-OSA at #ScientificSessions26. 🎥
1
7
1
22
1,985
Replying to @mirvatalasnag
@mirvatalasnag discusses late breaking science from SYNCHRONIZE-CVOT at #ScientificSessions26. 🎥
2
11
1
25
2,929
SYNCHRONIZE-CVOT results presented at #ScientificSessions26 In adults with obesity and established cardiovascular or chronic kidney disease, or increased cardiovascular risk, survodutide was non-inferior to placebo for a composite of cardiovascular death, non-fatal cardiovascular events, coronary revascularization, and heart failure events, while also improving cardiometabolic markers.
Image from AHA Science (@AHAScience)
3
6
428
SYNCHRONIZE-CVOT results presented at #ScientificSessions26 In adults with obesity and established cardiovascular or chronic kidney disease, or increased cardiovascular risk, survodutide was non-inferior to placebo for a composite of cardiovascular death, non-fatal cardiovascular events, coronary revascularization, and heart failure events, while also improving cardiometabolic markers.
This image contains a slide presentation about the SYNCHRONIZE-CVOT study. The study focuses on cardiovascular outcomes with Survodutide in adults with obesity at increased cardiovascular risk. Objectives, design, and conclusions of the study are summarized. An American Heart Association logo appears in the lower-left corner.

ALT This image contains a slide presentation about the SYNCHRONIZE-CVOT study. The study focuses on cardiovascular outcomes with Survodutide in adults with obesity at increased cardiovascular risk. Objectives, design, and conclusions of the study are summarized. An American Heart Association logo appears in the lower-left corner.

3
8
1
11
1,597
ATTAIN-OSA results presented at #ScientificSessions26 Among adults with moderate-to-severe OSA and overweight or obesity without diabetes, orforglipron significantly reduced apnea-hypopnea index compared with placebo at 52 weeks, both in participants using and not using positive airway pressure therapy.
Image from AHA Science (@AHAScience)
1
1
1
3
1,031
Load more